Welcome to our dedicated page for MRVFF news (Ticker: MRVFF), a resource for investors and traders seeking the latest updates and insights on MRVFF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MRVFF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MRVFF's position in the market.
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF), operating as Miravo Healthcare, will present at the Q1 Virtual Investor Summit on Tuesday, March 8, 2022, at 2:00 p.m. ET. CEO Jesse Ledger and CFO Mary-Jane Burkett will represent the company. The summit connects over 90 companies with more than 500 qualified investors across various sectors, including healthcare and biotechnology. Miravo focuses on a diversified portfolio of healthcare products targeting several therapeutic areas including pain and allergy.
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) will present at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The virtual event will feature Jesse Ledger, President & CEO, and Mary-Jane Burkett, VP & CFO, discussing the Company’s business overview. Interested investors can access the presentation starting at 7:00 a.m. ET on January 10. The Company focuses on healthcare products in areas like pain and allergy, supported by its operations in Canada and Ireland.
Miravo Healthcare (TSX:MRV, OTCQX:MRVFF) announced its participation in the SNN Network Canada Virtual Event 2021 on December 8, 2021, at 11:00 AM EST. President & CEO Jesse Ledger and CFO Mary-Jane Burkett will present and engage with investors. Interested participants can access the live presentation through the provided webcast link and can register for 1-on-1 meetings. Miravo focuses on healthcare solutions across various therapeutic areas, including pain and allergy management.
Nuvo Pharmaceuticals, operating as Miravo Healthcare, will present at the SNN Network Canada Virtual Event on December 8, 2021, at 11:00 a.m. ET. Jesse Ledger, President & CEO, and Mary-Jane Burkett, VP & CFO, will host the presentation and engage with investors. The event aims to provide insights into Miravo's diversified portfolio in healthcare, targeting areas like pain and allergy. Attendees can register for the event and access presentations via links provided.
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF), operating as Miravo Healthcare, announced an investor presentation webcast scheduled for December 2, 2021 at 2:00 p.m. ET. CEO Jesse Ledger and CFO Mary-Jane Burkett will present key business insights, followed by a live Q&A session. Investors can pre-register for the event and will have access to an archived version on the company’s website afterward. Miravo focuses on healthcare with a diverse product portfolio targeting pain, allergy, and dermatology.
Miravo Healthcare reported Q3 2021 adjusted total revenue of $17.1 million, a 3% increase year-over-year, while adjusted EBITDA rose 7% to $7.0 million. Prescription growth for key products Blexten and Cambia was strong, with increases of 16% and 5% respectively. However, total revenue for the nine months decreased by 4% to $51.6 million, alongside a 15% drop in adjusted EBITDA. The company made notable strides with the launch of Resultz in the U.S. and expanded its product lineup with pediatric use approval for Blexten.
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF), operating as Miravo Healthcare, announced its third-quarter 2021 financial results will be released on November 15, 2021, before market open. A conference call hosted by President & CEO Jesse Ledger is scheduled for the same day at 11:00 a.m. ET. Investors can access the audio webcast and replay through the provided link. Miravo focuses on various therapeutic areas including pain and neurology, and its operations adhere to strict Good Manufacturing Practices.
Nuvo Pharmaceuticals Inc. (MRVFF), operating as Miravo Healthcare, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be led by Jesse Ledger, President & CEO, and Mary-Jane Burkett, VP & CFO, offering insights into the company’s business strategy. Investors can register for the virtual conference to access over 750 presentations available live and on-demand starting at 7:00 a.m. ET on the first day.
Nuvo Pharmaceuticals (TSX: MRV, OTCQX: MRVFF) announced the expansion of the Blexten label for pediatric use, now approved for children as young as 4 years old. This includes new dosing formats: a 2.5mg/mL oral solution and a 10mg Quick Melt tablet. The Notice of Compliance from Health Canada signals an increase in the treatable patient population, with commercial availability expected in Q1 2022. This milestone enhances the Blexten franchise, providing patients with convenient and effective treatment options.
FAQ
What is the market cap of MRVFF (MRVFF)?
